DGX Stock Recent News

Parties to build state-of-the-art laboratory in Southfield to serve physicians and patients across the state Quest will also manage Corewell Health's 21 hospital labs SOUTHFIELD, Mich. and GRAND RAPIDS, Mich.

SECAUCUS, N.J. , Aug. 25, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the company's Haystack MRD® test for identifying MRD-positive patients with stage II colorectal cancer following curative-intent surgical treatment who may benefit from adjuvant therapy in accordance with therapeutic product labeling.

Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock?

DGX drives growth with advanced diagnostics, acquisitions and cost savings, but rising debt and macro risks weigh on its outlook.

OverviewIn a qui tam action filed under the False Claims Act, the relator, Barbara Senters, appealed the district court's dismissal of her fourth amended complaint (FAC), which alleged that Quest Diagnostics submitted false claims for medically unnecessary lab tests by using confusing “custom panels.” See United States ex rel Senters v. Quest Diagnostics, No. 24-12998 (11th Cir. 2025). The Eleventh Circuit affirmed the dismissal, finding the FAC did not satisfy the heightened factual pleading standards required by Federal Rule of Civil Procedure 9(b).Rule 9(b) Requires Particularity: The “Who, What, Where, When, and How” of a False ClaimA relator must plead with particularity the submission of a false claim—not just the existence of a fraudulent scheme. General allegations or inferences are insufficient. The complaint must identify a representative false claim and detail why it was false (e.g., medically unnecessary, knowingly submitted) and who submitted it, when, and how. T

SECAUCUS, N.J. , Aug. 15, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during the Baird 2025 Global Healthcare Conference in New York City on Wednesday, September 10, 2025, at 10:50 a.m.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

SECAUCUS, N.J. , Aug. 13, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.80 per share, payable on October 20, 2025 to shareholders of record of Quest Diagnostics common stock on October 3, 2025.

SECAUCUS, N.J. and BOSTON , Aug. 7, 2025 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, today announced a research collaboration with Mass General Brigham investigators at Massachusetts Eye and Ear and Massachusetts General Hospital, world-renowned centers for head and neck and advanced cutaneous oncology.

SECAUCUS, N.J. , Aug. 5, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the completion of its previously announced acquisition of select clinical testing assets of Fresenius Medical Care's wholly owned Spectra Laboratories, a leading provider of renal-specific laboratory testing services in the United States.